SBCM
TEVA icon

Silverberg Bernstein Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Silverberg Bernstein Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Sell
104,363
-57
-0.1% -$1.9K 1.35% 19
2026
Q1 		$3.15M Buy
104,420
+9,103
+10% +$293K 1.73% 17
2025
Q4 		$2.97M Buy
95,317
+4,000
+4% +$98.5K 1.72% 18
2025
Q3 		$1.84M Buy
91,317
+6,000
+7% +$105K 1.12% 26
2025
Q2 		$1.43M Buy
85,317
+13,157
+18% +$212K 0.98% 31
2025
Q1 		$1.11M Buy
72,160
+3,720
+5% +$66.5K 1.03% 28
2024
Q4 		$1.51M Sell
68,440
-600
-0.9% -$10.9K 1.33% 19
2024
Q3 		$1.24M Buy
69,040
+1,800
+3% +$31.5K 1.14% 22
2024
Q2 		$1.09M Hold
67,240
– – 1.06% 26
2024
Q1 		$949K Hold
67,240
– – 0.93% 29
2023
Q4 		$702K Buy
+67,240
New +$628K 0.67% 32

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Silverberg Bernstein Capital Management's TEVA Position: Q2 2026 in Review

Silverberg Bernstein Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 0.05% in Q2 2026, selling an estimated $1.9K and leaving 104,363 shares worth $3.54M. The position accounts for 1.35% of the portfolio, ranked #19.

Silverberg Bernstein Capital Management first reported a position in TEVA in Q4 2023 and has held it in 11 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Silverberg Bernstein Capital Management held 104,363 shares of Teva Pharmaceuticals worth $3.54M as of Q2 2026.
  • Silverberg Bernstein Capital Management sold 57 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.9K.
  • Teva Pharmaceuticals made up 1.35% of Silverberg Bernstein Capital Management's portfolio in Q2 2026, its #19 holding.
  • Silverberg Bernstein Capital Management first reported a position in Teva Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q2 2026, filed 7 Jul 2026.